Drug Profile
Laruparetigene zosaparvovec - Beacon Therapeutics
Alternative Names: AGTC-501; BIIB-088; rAAV2tYF-GRK1-RPGRLatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Applied Genetic Technologies Corporation
- Developer Beacon Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Retinitis pigmentosa
Most Recent Events
- 08 Feb 2024 Updated efficacy and adverse events data from a phase-I/II Skyline trial in X-linked retinitis pigmentosa released by Beacon Therapeutics
- 09 Jun 2022 9359990 - No updates
- 16 May 2022 Updated efficacy and adverse events data from a phase-I/II trial in X-linked retinitis pigmentosa released by Applied Genetic Technologies Corporation